Grants and Contributions:

Molecular Assay for Instrumentless SARS-CoV-2 Rapid Diagnostic from Saliva

956621

$100,000.00

Sep 6, 2020 - Dec 7, 2020

LFAnt is developing two distinct proof-of-concept instrument-less colorimetric liquid assays for the rapid saliva-based detection of (1) the SARS-CoV-2 virus and (2) its associated antibodies. LFANT's colorimetric liquid assay technology is based on the salt-induced aggregation and change in colour of aptamer-shielded gold nanoparticle (AuNP) solutions in the presence of aptamer-specific molecular targets. This Project includes the development of both novel reagent and assay solutions for potential integration into a saliva collection and processing device being developed by the NRC to provide a sample-to-answer system capable of detecting SARS-CoV-2 and COVID-19 immune response, respectively, within 15 minutes using only a simple visual result readout.

National Research Council Canada

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Dorval, Quebec, CA H9S 1T3

172-2020-2021-Q2-956621

Grant

Grants and Contributions

708315684

For-profit organization

LFAnt Medical

Dorval–Lachine–LaSalle

24024

Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

541710